Hypogonadism in Young Men With Type 2 Diabetes

University at Buffalo (UB)

Status and phase: Terminated; Phase 2

Conditions: Hypogonadotropic Hypogonadism; Type 2 Diabetes

Treatments: Drug: clomiphene; Drug: placebo; Drug: testosterone

Study type: Interventional

Funder types: Other

Identifiers

NCT01155518

1-10-JF-13

Details and patient eligibility

About

Low testosterone production, known clinically as hypogonadism, appears to be common complication of type 2 diabetes, affecting one in three diabetic men. Hypogonadism is known to be associated with decreased muscle mass, increased fat mass, increased inflammation and decreased fertility. In this grant, the investigators propose to study the effects of having low testosterone on 1) insulin sensitivity, the ability of the body to handle glucose 2) fat and muscle mass at specific areas of the body 3) expression of mediators of inflammation in the blood 4) semen quality. This study will compare diabetic men (with or without hypogonadism). This study will also evaluate the effect of treatment with clomiphene (a drug that increases testosterone and sperm production) or testosterone in men with diabetes and hypogonadism. The investigators hope that this project will help us understand the state of hypogonadism in young type 2 diabetic men who are in their peak fertility years and give us insights into treatment of this condition. With the rising prevalence of type 2 diabetes in the young, this project may have implications for public health.

Full description

This project will study young men with type 2 diabetes. We have shown that half of these men have low testosterone levels. This can lead to 1) Low muscle mass; 2) more fat mass; 3) insulin resistance; 4) low sperm count and 5) increased inflammation (that increases the risk of heart disease). This project will study these consequences in detail and also the possibility of reversing them with treatment. Information from this project will be useful in planning of future studies that will evaluate the effect of treatment of low testosterone on mortality, heart disease and stroke.

Enrollment: 5 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• T2D Males with age 18-40 years

Exclusion criteria

1. planning to have children in the next one year
2. Use of androgens, CC, hCG, aromatase inhibitors or over the counter health supplements which contain androgens currently or in the past 6 months;
3. PSA > 4ng/ml, symptoms of severe BPH, prostate nodule or severe enlargement on digital rectal examination or h/o prostatic carcinoma
4. Hemoglobin A1c > 8%
5. Hematocrit > 50%
6. History of obstructive sleep apnea
7. Congestive heart failure
8. Use of thiazolidinediones or exenatide
9. currently suffering from depression, with or without treatment
10. history of severe depression in the past which needed hospitalization
11. currently suffering from foot ulcer, significant periodontal disease or any other chronic infectious condition
12. Coronary event or procedure in the previous 6 months
13. Hepatic disease (transaminase > 3 times normal) or cirrhosis
14. Renal impairment (serum creatinine > 1.5)
15. HIV or Hepatitis C positive status
16. Participation in any other concurrent clinical trial

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

5 participants in 6 patient groups, including a placebo group

testosterone

Experimental group

Description:

intramuscular injections every 2 weeks

Treatment:

Drug: testosterone

clomiphene

Experimental group

Description:

oral drug thrice a week

Treatment:

Drug: clomiphene

placebo for testosterone

Placebo Comparator group

Description:

placebo for testosterone arm

Treatment:

Drug: placebo

Drug: placebo

placebo for clomiphene

Placebo Comparator group

Description:

oral placebo for clomiphene arm

Treatment:

Drug: placebo

Drug: placebo

eugonadal obese

No Intervention group

Description:

obese men with normal testosterone level

lean

No Intervention group

Description:

healthy lean men (control)